Highest-materiality recent filing
CVRx CFO Jared Oasheim steps down, will remain as advisor through February 2027
Jared Oasheim notified CVRx of his resignation as CFO on June 7, 2026, to pursue other opportunities.
CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance
U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.
CVRx reports preliminary Q1 2026 revenue $14.7-14.8M, +20% YoY; gross margin 87%
Revenue expected $14.7-14.8M vs $12.3M in Q1 2025, ~20% growth.
CVRx Q4 2025 revenue $16.0M (+4% YoY); net loss $11.9M; FY2026 rev guidance $63-67M
Q4 revenue $16.0M (US $14.9M, Europe $1.1M); gross margin 86% vs 83% YoY.
CVRx amends debt facility to $100M, draws $10M; Q4 rev ~$16M (+4-5% YoY)
Debt facility increased by $50M to $100M; $10M drawn at closing, total outstanding $60M; maturity extended to May 2031.
CVRx Q3 2025 revenue $14.7M (+10% YoY), net loss $12.9M; CMS approves favorable CPT codes for 2026
Total revenue $14.7M, up 10% YoY; U.S. revenue $13.5M (+10%); Europe revenue $1.2M (+12%).
CVRx Q2 revenue up 15% to $13.6M; narrows FY25 guidance; names COO
Q2 2025 revenue $13.6M (+15% YoY); U.S. HF revenue $12.1M (+15%); net loss $14.7M ($0.57/share).
CVRx Q1 revenue $12.3M (+15% YoY); net loss narrows; guides FY2025 rev $55-58M
Total revenue $12.3M (+15% YoY); U.S. HF revenue $11.1M (+14%) on 353 implants.
Preliminary Q1 2025 revenue ~$12.3M, up 15% YoY from $10.8M.
CVRx Q4 2024 revenue $15.3M (+36% YoY); FY2025 revenue guidance $63-65M
Q4 2024 total revenue $15.3M, +36% YoY; U.S. HF revenue $14.3M, +41% YoY (457 units vs 330).
CVRx reports Q4 2024 preliminary revenue $15.2-15.3M (+35% YoY), issues FY2025 guidance $63-65M
Q4 2024 revenue $15.2–15.3M, up 35% from $11.3M; U.S. $14.2–14.3M, Europe $1.0M.
CMS assigns Barostim to APC 1580; payment ~$45,000 continues in 2025
Centers for Medicare and Medicaid Services assigned Barostim procedure to New Technology APC 1580.
CVRx Q3 revenue rose 27% to $13.4M; net loss widened to $13.1M
US HF revenue $12.2M (+30% YoY) driven by territory expansion and new accounts.
CVRx draws $20M final tranche from Innovatus, total debt reaches $50M
Borrowed $20.0 million under the third and final tranche of its term loan facility with Innovatus Life Sciences Fund I, LP on Sept 30, 2024.
CVRx Q2 2024 revenue up 24% to $11.8M; net loss widens to $14.0M; updates FY guidance
Q2 2024 revenue $11.8M (+24% YoY); U.S. HF revenue $10.5M (+27% YoY); net loss $14.0M ($0.65/share) vs $11.6M ($0.56) in Q2 2023.
CVRx Q1 revenue $10.8M (+35% YoY); net loss $22.2M; FY guidance $50-53M
Q1 revenue $10.8M (+35% YoY); US HF revenue $9.7M (+43%); active implanting centers 190 (+56% YoY).
CVRx appoints Kevin Hykes as President and CEO effective Feb 12, 2024; Yared retires
Hykes, a board member since Dec 2022, succeeds Nadim Yared who retires Feb 11, 2024 and will consult through Dec 2024 at $550/hr.
CVRx Q4 revenue $11.3M (+58% YoY); CEO Nadim Yared to retire; FY23 rev $39.3M (+75%)
Q4 revenue $11.3M (+58% YoY); US HF revenue $10.2M (+70% YoY).
CVRx reports prelim Q4 revenue ~$11.2M (+57% YoY), FY2023 ~$39.2M (+74%); CEO Yared plans retirement
Preliminary Q4 2023 revenue $11.2M-$11.3M, up 56-58% YoY from $7.2M.
FDA approved revised Instructions For Use for Barostim incorporating long-term BeAT-HF trial data (NYHA Class III/II, EF ≤35%, NT-proBNP <1600 pg/ml).
CVRx Q3 revenue up 70% to $10.5M, raises FY2023 revenue guidance
Revenue $10.5M (+70% YoY); U.S. HF revenue $9.4M (+92% YoY).
CVRx Q2 revenue $9.5M (+89% YoY); raises FY 2023 revenue guidance
Q2 total revenue $9.5M, +89% YoY; US HF revenue $8.3M, +119% YoY.
CVRx Q1 revenue $8.0M (+96% YoY); US HF sales surge 132%; raises full-year guidance
Net loss of $11.4M ($0.55 per share) vs $10.0M ($0.49) in prior year quarter.
CVRx BeAT-HF trial: safety endpoint met, symptom improvement shown; primary endpoint not significant
Safety: MANCE event-free rate of 97% (p<0.001).
Trial of 323 HFrEF patients did not reach statistical significance on primary composite endpoint of CV mortality and HF morbidity.
CVRx Q4 revenue $7.2M (+96% YoY); guides FY2023 revenue $35-38M
Q4 2022 total revenue $7.2M, up 96% vs prior year; US HF revenue $6.0M (+121% YoY).
CVRx reports preliminary Q4 revenue up ~91-94% YoY; FY2023 guidance $35-38M
Q4 2022 revenue $7.0-7.1M (+91-94% YoY); U.S. heart failure revenue $5.9M.
CVRx Q3 revenue $6.2M (+82% YoY); raises FY2022 guidance; secures $50M debt facility
Q3 revenue $6.2M (+82% YoY); US HF revenue $4.9M (+99% YoY) on expansion to 91 active implanting centers (from 38).
CVRx Q2 revenue $5.0M (+61% YoY); HF revenue up 90% in US; FY guidance raised
Revenue $5.0M (+61% YoY), US HF revenue $3.8M (+90% YoY) driven by territory expansion.
CVRx Q1 revenue $4.1M (+43% YoY); US HF revenue up 133% to $2.9M
Net loss $10.0M ($0.49 per share) vs $8.6M loss ($23.92 per share) in Q1 2021; weighted avg shares 20.45M.
CVRx posts Q4 revenue $3.7M (+75% YoY); FY2021 revenue $13.0M; guides FY2022 rev $20-23M
Q4 2021 revenue $3.7M, up 75% YoY; US HF revenue $2.7M, up 345%.
Preliminary Q4 2021 revenue $3.6-$3.7M, up 71-77% YoY vs $2.1M.
CVRx reports Q3 revenue $3.4M (+241% YoY); repays $20M loan
Q3 revenue $3.4M (241% YoY increase); U.S. HF revenue $2.5M vs $140K prior year.
CVRx Q2 revenue up 150% to $3.1M; IPO nets $133.3M
Total revenue $3.1M (+150% YoY); U.S. HF revenue $2.0M (from $65K).
CVRx completes IPO of 8.05M shares at $18.00, raising ~$144.9M
IPO closed July 2, 2021; 8,050,000 shares sold including full over-allotment exercise.
On June 7, 2026, Jared Oasheim, the Chief Financial Officer (“CFO”) of CVRx, Inc. (the “Company”), gave notice of his intention to resign from the Company to pursue other professional opportunities.
On August 30, 2024, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) appointed Kevin Ballinger and Mitch Hill as directors, effective September 3, 2024.
On August 30, 2024, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) appointed Kevin Ballinger and Mitch Hill as directors, effective September 3, 2024.
On August 27, 2024, Ali Behbahani gave notice of his intention to resign from the Board effective at the close of business on September 2, 2024.
On January 31, 2024, CVRx, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Kevin Hykes as President and Chief Executive Officer (“CEO”), effective February 12, 2024.
Mr. Yared will retire from the Board at the time of his retirement as CEO and will consult with the Company to ensure a seamless transition.
its President and Chief Executive Officer, Nadim Yared, provided notice to the Company’s Board of Directors (the “Board”) of his plans to retire upon the completion of a deliberate succession process and the appointment of a successor.
On December 20, 2022, the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) approved an increase in the size of the Board from seven to eight members and appointed Kevin Hykes as a director effective December 21, 2022.
the Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) approved an increase in the size of the Board from seven to eight members and appointed Martha Shadan as a director effective July 12, 2021.
Max materiality 0.90 · Median 0.70 · Most common event earnings